| Symbol | ADIL |
|---|---|
| Name | ADIAL PHARMACEUTICALS, INC. |
| Sector | HEALTH CARE |
| Region | UNDEFINED |
| Industry | Pharmaceutical Preparations |
| Address | 1180 SEMINOLE TRAIL, CHARLOTTESVILLE, VA 22901 |
| Telephone | 434-422-9800 |
| Fax | — |
| — | |
| Website | https://www.adialpharma.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | — |
| Description | Adial Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company develops prescription medications for addiction and related disorders. Its lead product is AD04, which is for the treatment of alcohol use disorder. Additional info from NASDAQ: |
Adial Pharmaceuticals Successfully Completes Manufacturing of Demonstration Batch Production, Enabling Clinical and Registration Production for AD04 Planned Phase 3 Trial
Read moreAdial Pharmaceuticals Successfully Completes Manufacturing of Demonstration Batch Production, Enabling Clinical and Registration Production for AD04 Planned Phase 3 Trial
Read moreCary Claiborne on the Big Biz Show: A targeted approach to Alcohol Use Disorder
Read moreDirector Goodman Tony 🟢 acquired 26.5K shares of ADIAL PHARMACEUTICALS, INC. (ADIL) Transaction Date: Apr 07, 2026 | Filing ID: 042054
Read moreDirector Anderson J. Kermit 🟢 acquired 9.2K shares (1 derivative) of ADIAL PHARMACEUTICALS, INC. (ADIL) at $1.64 Transaction Date: Apr 07, 2026 | Filing ID: 042055
Read more(99% Neutral) ADIAL PHARMACEUTICALS, INC. (ADIL) Announces Executive Changes
Read moreDirector Schuyler Kevin 🟢 acquired 9.2K shares of ADIAL PHARMACEUTICALS, INC. (ADIL) Transaction Date: Apr 07, 2026 | Filing ID: 042052
Read moreShah Vinay 🟢 acquired 17.3K shares of ADIAL PHARMACEUTICALS, INC. (ADIL) Transaction Date: Apr 07, 2026 | Filing ID: 042053
Read moreDirector Gilliland Robertson H. 🟢 acquired 9.2K shares of ADIAL PHARMACEUTICALS, INC. (ADIL) Transaction Date: Apr 07, 2026 | Filing ID: 042051
Read moreDirector Claiborne Cary J 🟢 acquired 38.0K shares of ADIAL PHARMACEUTICALS, INC. (ADIL) Transaction Date: Apr 07, 2026 | Filing ID: 042050
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT04387773 | Effect of GOCOVRI (Amantadine, Extended Release Capsules) on Gait in Parkinson'… | Phase4 | Parkinson Disease | Completed | 2020-11-05 | 2022-09-30 | ClinicalTrials.gov |
| NCT04101227 | Study to Evaluate AD04 in Adults With Alcohol Use Disorder (AUD) and Selected S… | Phase3 | Alcohol Use Disorder | Completed | 2020-02-01 | 2022-03-18 | ClinicalTrials.gov |
| NCT03567057 | A Safety and Efficacy Study of ADS-5102 in Patients With Multiple Sclerosis and… | Phase3 | Multiple Sclerosis | Completed | 2018-07-18 | 2021-04-18 | ClinicalTrials.gov |
| NCT02471222 | Safety and Efficacy of ADS-5102 in Patients With Multiple Sclerosis and Walking… | Phase2 | Walking Impairment | Completed | 2015-05-01 | 2016-06-01 | ClinicalTrials.gov |
| NCT02153645 | Efficacy and Safety of Amantadine Hydrochloride (HCl) ER Tablets to Treat Parki… | Phase3 | Parkinson's Disease | Terminated | 2014-08-18 | 2016-05-20 | ClinicalTrials.gov |
| NCT02153632 | Efficacy and Safety of Amantadine Hydrogen Chloride (HCl) ER Tablets in Parkins… | Phase3 | Parkinson's Disease | Terminated | 2014-07-30 | 2016-05-20 | ClinicalTrials.gov |
| NCT02202551 | Open-Label Safety Study of ADS-5102 in PD Patients With LID | Phase3 | Dyskinesia | Completed | 2014-07-01 | 2018-02-01 | ClinicalTrials.gov |
| NCT02136914 | ADS-5102 for the Treatment of Levodopa Induced Dyskinesia (EASE LID Study) | Phase3 | Dyskinesia | Completed | 2014-05-01 | 2015-12-01 | ClinicalTrials.gov |
| NCT01397422 | Extended Release Amantadine Safety and Efficacy Study in Levodopa-Induced Dyski… | Phase2 | Dyskinesia | Completed | 2011-07-01 | 2013-10-01 | ClinicalTrials.gov |
| NCT00979251 | Oral Triple Combination Antiviral Drug Therapy for Treatment of Influenza A in … | Phase2 | Influenza | Completed | 2009-09-01 | 2011-08-01 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| ADS-8902 | DRUG | Phase PHASE2 | Influenza | COMPLETED | NCT00979251 |
| Oseltamivir Phosphate | DRUG | Phase PHASE2 | Influenza | COMPLETED | NCT00979251 |
| ADS-5102 (extended release amantadine HCl) | DRUG | Phase PHASE2 | Dyskinesia | COMPLETED | NCT01397422 |
| ADS-5102 | DRUG | Phase PHASE2 | Walking Impairment | COMPLETED | NCT02471222 |
| ADS-5102, 274 mg | DRUG | Phase PHASE3 | Multiple Sclerosis | COMPLETED | NCT03567057 |
| 320mg Amantadine HCl ER tablets | DRUG | Phase PHASE3 | Parkinson's Disease | TERMINATED | NCT02153645 |
| Placebo tablets | DRUG | Phase PHASE3 | Parkinson's Disease | TERMINATED | NCT02153645 |
| 240mg Amantadine HCl ER tablets | DRUG | Phase PHASE3 | Parkinson's Disease | TERMINATED | NCT02153645 |
| Placebo | OTHER | Phase PHASE2 | Walking Impairment | COMPLETED | NCT02471222 |
| amantadine HCl ER | DRUG | Phase PHASE3 | Parkinson's Disease | TERMINATED | NCT02153632 |
| GOCOVRI | DRUG | Phase PHASE4 | Parkinson Disease | COMPLETED | NCT04387773 |